Brelgometon

LeonaBio, formerly called Athira Pharma, is a small Nasdaq-listed biotech in Bothell, Washington. Its closely related drug fosgonimeton failed a large Alzheimer's trial in 2024. In 2026 the company shifted its main focus to lasofoxifene, a breast cancer drug, and said it would update the ALS timeline later.

HGF (hepatocyte growth factor) is a natural signal that helps nerve cells survive and reduces inflammation. Brelgometon is designed to strengthen this signal. The company's earlier drug, fosgonimeton, works the same way and failed to help people with Alzheimer's disease in a Phase 2/3 trial in 2024.

The only human study gave single doses, or 10 days of daily doses, of brelgometon or placebo to 80 healthy adults in Dallas, and finished in November 2024. In 2025 the company said it would start a trial in people with ALS in late 2025; that did not happen. In May and June 2026 it said a Phase 2 trial would start in the second half of 2026, then in August 2026 withdrew that timing.

No one with ALS has taken brelgometon. In healthy volunteers it was safe and reached the brain and spinal cord. The company reports that in ALS mice it reduced nerve damage, inflammation and TDP-43 clumps and helped them live longer. These are mouse results; most drugs that work in mice do not work in people.

This is the most favourable result reported. See all key studies for the full picture.

The company is developing brelgometon for ALS in general, not a genetic subgroup. In the healthy volunteer study it was given by mouth as a liquid, once a day.

In August 2026 LeonaBio said it would give an update on the ALS trial's timing once enrolment in its breast cancer trial, ELAINE-3, is complete, which it expects in late 2026. It has not given a new date for the ALS trial.

The only trial, in healthy volunteers, has finished. There is no trial open to people with ALS and we found no expanded access programme.

• ATH-1105 Phase 1 (healthy volunteers) (NCT06432647) completed · Dallas TX